
Janssen says combination Phase III study for immunotherapy Darzalex for multiple myeloma shows significant PFS
pharmafile | June 6, 2016 | News story | Research and Development, Sales and Marketing | ASCO, Drig Trial, Janssen, multiple myeloma
Janssen said combination late stage trials for its immunotherapy drug to treat multiple myeloma showed 61% progression-free survival.
The company said its Darzalex (daratumumab) also significantly increased the overall response rate in Phase III study.
Jane Griffiths, company group chairman, Janssen Europe, Middle East and Africa, said: “The findings provide an important insight into the effect daratumumab can have in combination with established regimens, and illustrate the promise of this immunotherapy in earlier lines of treatment.”
Darzalex was studied in combination with bortezomib (a proteasome inhibitor [PI]) and dexamethasone (a corticosteroid).
Antonio Palumbo, myeloma unit chief, department of oncology, division of haematology, University of Torino, Italy, said: “We saw clinically meaningful improvements in progression-free survival and overall response rates with daratumumab when combined with standard of care. These compelling Phase III results demonstrate that a regimen built on daratumumab deepens clinical responses and help to underscore its potential for multiple myeloma patients who have been previously treated.”
Anjali Shukla
Related Content

Sanofi’s Sarclisa gains EU approval for multiple myeloma treatment
Sanofi has received approval from the European Commission for the use of Sarclisa (isatuximab) in …

CHMP issues positive opinion for Blenrep combinations in relapsed/refractory multiple myeloma
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) …

Novartis releases new data across oncology and haematology pipelines
Novartis has announced it will present new data at the 2025 American Society of Clinical …






